FDA Approval of Drugs Not Meeting Pivotal Trial Primary End Points
JAMA Internal Medicine
FEBRUARY 12, 2023
This cross-sectional study determines the frequency of and rationale for US Food and Drug Administration (FDA) approval of drugs not meeting pivotal trial primary efficacy end points.
Let's personalize your content